PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Antithrombotics - Market size and forecast 2018-2023 Antihyperlipidemics - Market size and forecast 2018-2023 Antihypertensives - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Entry of generic drugs Technological advances in medical devices Increasing demand for curative therapies PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Amgen Inc. AstraZeneca Plc Boehringer Ingelheim International GmbH Bristol-Myers Squibb Co. Eli Lilly and Co. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co., Inc. Pfizer Inc. Sanofi PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Antithrombotics - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Antithrombotics - Year-over-year growth 2019-2023 (%) Exhibit 22: Antihyperlipidemics - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Antihyperlipidemics - Year-over-year growth 2019-2023 (%) Exhibit 24: Antihypertensives - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Antihypertensives - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Amgen Inc. - Vendor overview Exhibit 51: Amgen Inc. - Business segments Exhibit 52: Amgen Inc. - Organizational developments Exhibit 53: Amgen Inc. - Geographic focus Exhibit 54: Amgen Inc. - Key offerings Exhibit 55: Amgen Inc. - Key customer Exhibit 56: AstraZeneca Plc - Vendor overview Exhibit 57: AstraZeneca Plc - Business segments Exhibit 58: AstraZeneca Plc - Organizational developments Exhibit 59: AstraZeneca Plc - Geographic focus Exhibit 60: AstraZeneca Plc - Key offerings Exhibit 61: AstraZeneca Plc - Key customers Exhibit 62: Boehringer Ingelheim International GmbH - Vendor overview Exhibit 63: Boehringer Ingelheim International GmbH - Business segments Exhibit 64: Boehringer Ingelheim International GmbH - Organizational developments Exhibit 65: Boehringer Ingelheim International GmbH - Geographic focus Exhibit 66: Boehringer Ingelheim International GmbH - Segment focus Exhibit 67: Boehringer Ingelheim International GmbH - Key offerings Exhibit 68: Boehringer Ingelheim International GmbH - Key customers Exhibit 69: Bristol-Myers Squibb Co. - Vendor overview Exhibit 70: Bristol-Myers Squibb Co. - Business segments Exhibit 71: Bristol-Myers Squibb Co. - Organizational developments Exhibit 72: Bristol-Myers Squibb Co. - Geographic focus Exhibit 73: Bristol-Myers Squibb Co. - Key offerings Exhibit 74: Bristol-Myers Squibb Co. - Key customers Exhibit 75: Eli Lilly and Co. - Vendor overview Exhibit 76: Eli Lilly and Co. - Business segments Exhibit 77: Eli Lilly and Co. - Organizational developments Exhibit 78: Eli Lilly and Co. - Geographic focus Exhibit 79: Eli Lilly and Co. - Segment focus Exhibit 80: Eli Lilly and Co. - Key offerings Exhibit 81: Eli Lilly and Co. - Key customers Exhibit 82: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 83: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 84: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 85: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 86: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 87: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 88: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 89: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 90: Johnson & Johnson Services, Inc. - Business segments Exhibit 91: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 92: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 93: Johnson & Johnson Services, Inc. - Segment focus Exhibit 94: Johnson & Johnson Services, Inc. - Key offerings Exhibit 95: Johnson & Johnson Services, Inc. - Key customers Exhibit 96: Merck & Co. Inc. - Vendor overview Exhibit 97: Merck & Co. Inc. - Business segments Exhibit 98: Merck & Co. Inc. - Organizational developments Exhibit 99: Merck & Co. Inc. - Geographic focus Exhibit 100: Merck & Co. Inc. - Segment focus Exhibit 101: Merck & Co. Inc. - Key offerings Exhibit 102: Merck & Co. Inc. - Key customers Exhibit 103: Pfizer Inc. - Vendor overview Exhibit 104: Pfizer Inc. - Business segments Exhibit 105: Pfizer Inc. - Organizational developments Exhibit 106: Pfizer Inc. - Geographic focus Exhibit 107: Pfizer Inc. - Segment focus Exhibit 108: Pfizer Inc. - Key offerings Exhibit 109: Pfizer Inc. - Key customers Exhibit 110: Sanofi - Vendor overview Exhibit 111: Sanofi - Business segments Exhibit 112: Sanofi - Organizational developments Exhibit 113: Sanofi - Geographic focus Exhibit 114: Sanofi - Segment focus Exhibit 115: Sanofi - Key offerings Exhibit 116: Sanofi - Key customers Exhibit 117: Validation techniques employed for market sizing Exhibit 118: Definition of market positioning of vendors

Amgen Inc. AstraZeneca Plc Boehringer Ingelheim International GmbH Bristol-Myers Squibb Co. Eli Lilly and Co. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co., Inc. Pfizer Inc. Sanofi